MacuCLEAR is a specialty clinical-stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye. Founded in 2006 and based in Plano, TX, it is led by president and CEO Phillip G. Ralston. Its lead product, MC-1101, is a topically administered eye drop intended to treat and stop progression of early-stage (Dry) AMD to late-stage (Wet) AMD by increasing ocular blood flow in the choroidal vessels. The company intends to use the recent funds to complete a pivotal Phase 3a human efficacy trial for MC-1101. MacuCLEAR has entered a strategic partnership with a Pacific Rim pharmaceutical partner and investor to finance clinical costs, bridging studies and regulatory development for MC-1101 in that territory. The company also maintains a portfolio of 11 additional compounds in development for diabetic retinopathy, second-generation AMD treatments and other vascular diseases of the eye.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2012